Abstract. In order to explore the potential effects of interleukin (IL)-35 on IL-10, transforming growth factor-β (TGF-β), interferon-γ (INF)-γ, IL-12 and IL-17, a pcDNA3.1-IL-35 plasmid was injected into the vitreous cavity of BALB/c mice. Enzyme-linked immunosorbent assay, western blot analysis and quantitative PCR analysis were performed to confirm the successful expression of IL-35. Slit-lamp biomicroscopy, hematoxylin and eosin staining and immunofluorescence were employed to detect the status of eyes, and western blot analysis was performed to examine the expression of corneal graft rejection-related cytokines. There were no abnormalities in the eyes pre-mydriasis or post-mydriasis and no injuries to the cornea or retina following the injection of IL-35-expressing plasmid. An immunofluorescence assay detected the positive expression of IL-35 in corneal epithelial cells from IL-35-injected mice and negative staining in the control group. Further study revealed that IL-35 enhanced the expression of IL-10 and TGF-β which reached their highest levels at 1 and 2 weeks after injection, respectively (p<0.01). Moreover, the expression of INF-γ and IL-12 was decreased significantly at 2 weeks after the injection of IL-35-expressing plasmid (p<0.05), and the expression of IL-17 was suppressed notably at 4 weeks after the injection (p<0.05). The intravitreal injection of IL-35-expressing plasmid in mice downregulates the expression of pro-inflammatory cytokines and upregulates the expression of anti-inflammatory cytokines. Thus, IL-35 may further be assessed as a potential target for the treatment of corneal graft rejection.
Introduction
The cornea is an immunologically privileged area, and keratoplasty is one of the most successful forms of solid tissue transplantation that serves as the only clinical therapy for blindness (1) . Approximately 36,000 cases of corneal transplantation surgery are performed annually in the USA and about 3,000 cases in China each year (2, 3) . Despite steady improvements in the graft survival rate, immune-mediated graft rejection remains the major cause of human corneal allograft failure, particularly following high-risk keratoplasty or a second keratoplasty (4, 5) . Currently, glucocorticoids, cyclosporin A and tacrolimus are the main clinical treatment strategies for corneal graft rejection; however, treatment is limited by the non-specific inhibition of immune defense function. Hence, specific local therapeutic approaches are expected to prolong the survival time of corneal grafts. CD4 + T-cells play an important role in corneal graft rejection (6) . Activated naive CD4 + T-helper cells (Th0) differentiate into Th1, Th2 or Th3 cell subsets depending on the different kinds of cytokines within the graft microenvironment. The Th cells were then activated by recognizing alloantigens to secrete a series of cytokines including IL-10, interferon-γ (INF-γ) and transforming growth factor-β (TGF-β) (7) .
Interleukin (IL)-35, a heterodimer composed of p35 and Epstein-Barr virus-induced gene 3 (EBI3) subunits, belongs to the IL-12 family and exerts anti-inflammatory and immunomodulatory effects (8) . It is predominantly expressed by thymus-derived and peripheral CD4 + CD25 + Foxp3 + regulatory T (Treg) cells (9) . Previous findings have demonstrated that the elevated serum IL-35 level was associated with the inflammatory response in multiple inflammatory diseases such as acute pancreatitis (10) , collagen-induced arthritis (CIA) (11) , periodontal inflammation (12) , allergic rhinitis and asthma (13) as well as coronary artery disease. In vitro studies demonstrated that animals without functional IL-35 exhibited enhanced inflammatory immune responses and were more likely to develop diseases, such as liver fibrosis, inflammatory bowel disease and models of lethal autoimmune disease (14) (15) (16) (17) . Furthermore, reduced IL-35 levels are associated with rejection following allogeneic hematopoietic stem cell transplantation (10) , and IL-35 therapy may inhibit cardiac allograft rejection in mice (18) . Jin et al demonstrated that the expression of IL-35 in human placental trophoblasts may prevent matrix immune rejection induced by fetal antigens (19) . However, the effect of IL-35 on other corneal graft rejection-related cytokines in the eyes has not been substantiated.
In the present study, we successfully injected a pcDNA3.1-IL-35 plasmid into the mouse vitreous cavity to observe whether IL-35 affected the expression of corneal graft rejection-related cytokines. Our results showed that intravitreal injection of pcDNA3.1-IL-35 plasmid is safe for mouse eyes. Furthermore, enhanced levels of IL-35 may suppress pro-inflammatory cytokine expression and increase anti-inflammatory cytokine expression.
Materials and methods

Animals.
A total of 72 specific pathogen-free (SPF) female BALB/c mice, aged 6-10 weeks old and weighing between 15-18 g were purchased from the Medical Laboratory Animal Center of Sun Yat-sen University (Guangzhou, China). This study was approved by the Ethics Committee of Sun Yat-sen University. All animal experiments were performed in accordance with the Guidelines of Institutional Animal Care and Use Committee at Sun Yat-sen University.
Intravitreal injection of pcDNA3.1-IL-35 plasmid. The pcDNA3.1-IL-35 plasmid harboring IL-35-coding sequences was constructed by Guangzhou Vipotion Biotechnology Co., Ltd. (Guangzhou, China). Each mouse was deeply anesthetized by an intraperitoneal injection of 4.3% chloral hydrate (China National Medicines Corporation, Ltd., Beijing, China) and mydriasis was induced with tropicamide eye drops (Shenyang Xingqi Pharmaceutical Co., Ltd., Shenyang, China). To induce superficial anesthesia of the eye, 0.5% tetracaine hydrochloride (National Institutes for Food and Drug Control, Beijing, China) was subsequently used. A 33 g Hamilton microinjector was used to puncture the vitreous cavity at a 45˚ angle to the transection of the lens and 1 µl (1 µg/µl) pcDNA3.1-IL-35 plasmid was injected into vitreous cavity. Subsequently, tobramycin (Qilu Pharmaceutical Co., Ltd., Jinan, China) was applied to the conjunctival sac. Equal volumes of pcDNA3.1 plasmid and PBS were injected in parallel as a control. Ocular status (pre-mydriasis and post-mydriasis) was examined by slit-lamp biomicroscopy 1, 2 and 4 weeks after injection and 6-8 mice in each group were then sacrificed by cervical dislocation. The mouse eyes were enucleated for subsequent experiments.
Enzyme-linked immunosorbent assay (ELISA).
The enucleated eyes in each mouse were lysed according to a previously published method (20) . Thereafter, ELISA was peformed using a mouse ELISA kit for IL-35 (USCN Business Co., Ltd., Wuhan, China) strictly according to the manufacturer's instructions, with five replicates for each testing point including blank wells and untreated controls (0 week). Optical density (OD) values were assessed at 450 nm by a microplate reader (Biotek, Winooski, VT, USA).
Western blot analysis. The enucleated eyes from each mouse were lysed and the total proteins were extracted as previously described (20) , and the protein concentration was quantified using a bicinchoninic acid (BCA) protein assay kit (Beyotime Institute of Biotechnology, Haimen, China). Proteins (40 µg) in each sample were loaded and separated using sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto polyvinylidene fluoride (PVDF) membranes (Millipore, Bedford, MA, USA). The membranes were then blocked with 5% non-fat milk overnight and probed with anti-p35 (ab66064), anti-IL-10 (ab134742), anti-TFG-β (ab190503), anti-IFN-γ (ab24324), anti-IL-12 (ab89889) and anti-IL-17 (ab77171) primary antibodies (1:500 dilution; all from Abcam, Cambridge, MA, USA) at 4˚C overnight, followed by incubation with secondary anti-rabbit IgG-HRP antibody (A0208) or anti-mouse IgG-HRP antibody (A0216) (1:5000 dilution; Beyotime Institute of Biotechnology) at 37˚C for 45 min after washing twice with TBST. The target bands were visualized using enhanced chemiluminescence (ECL) solution (Qihai Biotec, Shanghai, China) and analyzed using Gel-ProAnalyzer software (Media Cybernetics, Bethesda, MD, USA). β-actin served as an internal control.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
The total RNA was extracted from the enucleated eyes using an RNA extraction kit (Tiangen Biotech, Beijing, China) and then reverse transcribed into cDNA. RT-qPCR reactions were performed in an Exicycler™ 96 (Bioneer, Daejeon, Korea) using SYBR-Green Master mix (Solarbio, Beijing, China) according to the following protocol: initial denaturation at 95˚C for 5 min, 30 cycles consisting of 95˚C for 20 sec, 60˚C for 20 sec, and 72˚C for 30 sec, and final elongation at 4˚C for 5 min. The primer sequences were as follows: p35, 5'-GACCTGGACCCTGAGATTGTGAA-3' (sense) and 5'-GGTCCCTGTGCAGCACGTTA-3' (antisense); and β-actin, 5'-GGAGATTACTGCCCTGGCTCCTA-3' (sense) and 5'-GACTCATCGTACTCCTGCTTGCTG-3' (antisense). Relative mRNA expression was calculated using the 2 -ΔΔCT method and β-actin was used as an internal control.
Hematoxylin and eosin (H&E) staining.
Corneal and retinal tissues were fixed in 10% formaldehyde for 24 h, dehydrated with a graded series of ethanol (70% for 2 h, 80% overnight, 90% for 2 h and 100% for 2 h) and embedded in dimethylbenzene-paraffin. Sections (5 µm) were cut, placed onto slides and dried in a 70˚C chamber for 40 min. After being dewaxed with ethanol, the sections were soaked with hematoxylin (Solarbio), water and 1% hydrochloric ethanol at room temperature for 5 min, 5 min, and 3 sec respectively, and rinsed with water for 20 min. The slices were subsequently stained with eosin for 3 min, and dehydrated through a graded series of ethanol (75, 85, 95% each for 2 min, and 100% twice for 5 min). The stained tissues were then permeabilized twice with xylene for 10 min and mounted with resinene and observed under a microscope (DP73; Olympus, Tokyo, Japan) and images were captured.
Immunofluorescence double staining. The 5 µm slices were fixed in 4% formaldehyde for 15 min, washed with PBS three times, and blocked with 10% bovine serum albumin (BSA) at room temperature for 1 h. Thereafter, the cells were co-incubated with p35 (sc-821; 1:50 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and EBI3 primary antibodies (sc-166158; 1:250 dilution; Santa Cruz Biotechnology) at 4˚C overnight and subsequently incubated with FITClabeled goat anti-rabbit IgG (H+L) (A0562) and Cy3-labeled goat anti-mouse IgG (H+L) (A0516) secondary antibodies (Beyotime Institute of Biotechnology) at a dilution of 1:200 for 1 h at room temperature. Unbound antibodies in each step were removed by washing with PBS. The coverslips were mounted inversely onto slides with 95% glycerol and observed under a laser scanning confocal microscope (Olympus) and images were captured.
Statistical analysis. Statistical analysis was performed using GraphPad Prism 5.0 software. All data are reported as the means ± standard deviation (SD). The differences between groups were analyzed by one-way analysis of variance (ANOVA). A p-value <0.05 was considered to indicate a statistically significant difference.
Results
Intravitreal injection of pcDNA3.1-IL-35 plasmid increases intraocular level of IL-35.
To explore the function of IL-35 in the eyes of mice, the pcDNA3.1-IL-35 plasmid encoding IL-35 was injected into the vitreous cavity of BALB/c mice, and then the expression level of IL-35 was detected by ELISA, RT-qPCR and western blot analysis. The results of the ELISA showed that the intraocular IL-35 level was significantly elevated at 1 week after injection with the pcDNA3.1-IL-35 plasmid compared with pcDNA3.1 injection (Fig. 1A; p<0 .01) and in fact, peaked after 1 week (20.43±1.032 pg/eyeball). Moreover, the mRNA levels of intraocular p35 at 1, 2 and 4 weeks after injection with the pcDNA3.1-IL-35 plasmid were 3.53-, 2.39 and 2.14-fold ( Fig. 1B; p<0 .001) higher, respectively, than those injected with with respective pcDNA3.1. The protein levels of intraocular p35 at 1, 2 and 4 weeks after IL-35 plasmid injection were 2.25-, 1.94-and 1.79-fold higher, respectively, (Fig. 1B and C; p<0.01) than those in the presence of pcDNA3.1 alone. These data suggest the successful expression of the pcDNA3.1-IL-35 plasmid in the mouse eyes.
Intravitreal injection of pcDNA3.1-IL-35 plasmid is safe to ocular tissues. To determine the effect of an intravitreal injection of pcDNA3.1-IL-35 plasmid on intraocular tissues, slit-lamp and H&E staining were employed to evaluate the physiological changes in the cornea and retina. As shown in Fig. 2A , there were no differences between the mouse eyes injected with pcDNA3.1-IL-35 plasmid and the control. The cornea exhibited transparency without obvious edema, the aqueous humor was clear, iris vessels were clearly visible, and the size and location of the pupil was normal. There was no intraocular hemorrhage, retinal detachment, or neovascularization during the 4 week period following plasmid injection. Further H&E staining revealed no abnormalities of the cornea in all groups except for the loose arrangement of corneal stroma collagen fibers which disappeared at 4 weeks after injection (Fig. 2B ). There were no apparent abnormalities in the retinal pigment epithelium, retinal cells, cell layer or bipolar cells, indicating that the method of intravitreal injection of pcDNA3.1-IL-35 plasmid is safe to ocular tissues.
IL-35 is uniformly distributed on corneal epithelial cells.
IL-35 is formed by pairing IL-12α (also known as p35) and EBI3. As IL-35 shares the p35 subunit with IL-12 and shares the EBI3 subunit with IL-27 (8), we employed the immunofluorescence double staining assay to identify the distribution of intraocular IL-35. As shown in Fig. 3 , there Fig. 5A; p<0.05) . Simultaneously, the expression of IL-12 was apparently decreased by 1.91-fold compared with the control at 2 weeks after the pcDNA3.1-IL-35 plasmid injection ( Fig. 5B; p<0.05 ). In addition, a marked downregulation of IL-17 was observed at 4 weeks after the pcDNA3.1-IL-35 plasmid injection ( Fig. 5C ; p<0.05). Taken together, these findings demonstrate that elevated IL-35 levels inhibit the expression of pro-inflammatory cytokines.
Discussion
The anti-inflammatory cytokine IL-35 is able to inhibit rejection following organ transplantation. However, the role of IL-35 in corneal graft rejection remains unclear, and the effect of IL-35 on corneal graft rejection-related cytokines has not been fully elucidated. Herein, we found that increased IL-35 expression promoted the expression of anti-inflammatory cytokines and reduced the expression of pro-inflammatory cytokines following an intravitreal injection of pcDNA3.1-IL-35 plasmid, which was also proved to be safe to use in ocular tissues as there were no abnormalities observed in the mouse corneal and retinal tissues. Collectively, these findings demonstrate that an intravitreal injection of plasmid harboring IL-35 may be a potential approach for reducing the risk of corneal allograft rejection.
The immunosuppressive effect of IL-35 is not only characterized by the suppression of effector T cell (Teff) responses and Teff proliferation, but is also manifested in the induction of Tregs to generate and propagate infectious tolerance, and these Tregs in turn secrete IL-35 to enhance the immunosuppressive effect (14, 15, 21) . Detailed studies have identified that Tregs play an essential role in protecting individuals against graft rejection and prolonging survival time, including corneal transplantation (22, 23) . In view of these findings, we hypothesized that IL-35 may contribute to the inhibition of corneal allograft rejection. Moreover, plasmid injection does not result in genomic integration, therefore the expression of foreign genes in the tissue cells is temporary, and the cells will gradually lose the plasmid over time (24) . Previous studies examined the hydrodynamic tail vein injection of plasmid DNA; however, efficient expression was only detected in the mouse liver (25) (26) (27) . Other studies found that an intravitreal injection of plasmid DNA led to expression in the cornea (28) (29) (30) . Thus, we preliminarily detected alterations in the expression of relevant cytokines after injecting the pcDNA3.1-IL-35 plasmid into the vitreous cavity of mice. We detected that the expression of IL-35 lasted for at least 4 weeks in corneal epithelial cells, which is concurrent with the occurrence time of an alloantigen-induced inflammatory reaction following corneal allograft surgery. IL-10 and TGF-β are secreted by a variety of cell types with graft tolerance and anti-inflammatory properties (31) . IL-10 may block the production of IL-12 and downregulate MHC class II expression on monocytes (32) . TGF-β regulates the proliferation, differentiation and apoptosis of several immune cells (33) . Jin et al proved that IL-35 boosted the proliferation of Tregs by increasing the expression of IL-10 and TGF-β, which was important for the establishment and maintenance of maternal-fetal tolerance during early pregnancy (19) . In this study, we demonstrated that the expression of IL-10 and TGF-β were significantly increased in the eyes following an intravitreal injection of pcDNA3.1-IL-35 plasmid, which was consistent with the previous findings of Jin et al. The elevated levels of IL-10 and TGF-β are closely associated with immune tolerance to the corneal allograft (34) (35) (36) . Klebe et al reported that transferred ovine IL-10-cDNA reduced the incidence of corneal graft rejection and prolonged corneal allograft survival (37). Wang et al found that TGF-β plays an important role in the conversion of Tregs from T-helper (Th)17 cells and thereby affects the Treg-Th17 balance to facilitate immunological tolerance following allogenic corneal transplantation (38) . Hence, we demonstrated that the exogenous injection of IL-35 upregulated the expression of the graft tolerance-related cytokines, IL-10 and TGF-β.
INF-γ is a potent, pro-inflammatory cytokine responsible for strengthening the Th1 immune response, and IL-12 is another pro-inflammatory cytokine capable of promoting the proliferation of Th1-type cells (39) . Recent evidence suggested that IL-12 stimulated IFN-γ production by NK and T cells (40) , and the increased production of IL-12 and IFN-γ may be predictive of corneal graft rejection (41, 42) . In our study, we detected the downregulation of IL-12 and IFN-γ in pcDNA3.1-IL-35 plasmid-injected eyes, indicating the presence of an anti-inflammatory environment around the cornea. Additionally, IL-17, a potent pro-inflammatory cytokine, mediates tissue inflammation by inducing chemokine expression and leukocyte infiltration (43) . The IL-17 antagonist prolonged the median survival time of non-vascularized and vascularized cardiac allograft patients and improved the survival rate of corneal allogeneic transplantation (44) (45) (46) . Chen et al observed that the anti-IL-17 mAb suppressed the expression of IFN-γ and IL-12 p40 significantly in transplanted splenocytes (46, 47) . Similarly, we found a notable decline in IL-17 expression 4 weeks after IL-35 injection and more significantly reduced IFN-γ and IL-12 levels at the same time point, suggesting that the decreased expression of IL-17 may further reduce IFN-γ and IL-12 levels. Taken together, these findings demonstrated that an intravitreal injection of pcDNA3.1-IL-35 plasmid downregulated the expression of the pro-inflammatory cytokines IL-12, IL-17 and IFN-γ.
There are some limitations in our study. We explored the effect of elevated IL-35 expression on corneal allograft rejection-related cytokines in healthy mice without establishing a model of corneal allograft rejection. In our next study, we will detect IL-35 distribution and pathological changes in other ocular tissues following an intravitreal injection of pcDNA3.1-IL-35 plasmid in a murine model of corneal allograft transplantation.
The findings of the present study suggest that an intravitreal injection of IL-35 plasmid suppresses the expression of pro-inflammatory cytokines and promotes the expression of anti-inflammatory cytokines. Our data preliminarily identified the effects of IL-35 on corneal allograft rejection-related cytokines, and suggest that IL-35 may serve as a potential target for gene therapy of corneal allograft rejection.
